Hoth Therapeutics First in Human Clinical Trial for the Treatment of Atopic Dermatitis with BioLexa is Underway
News provided by
Share this article
Share this article
NEW YORK, April 22, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a clinical-stage biopharmaceutical company focused on developing new generation therapies for unmet medical needs, is pleased to announce the start of its First in Human clinical trial investigating topical BioLexa for the treatment of mild to moderate atopic dermatitis, also known as eczema. We are excited to have reached this pivotal milestone in our BioLexa development program, stated Robb Knie, CEO of Hoth Therapeutics. There continues to be an unmet need for improved therapeutics for patients suffering from mild to moderate eczema. The BioLexa clinical trial brings us one step closer to potentially improve the quality of life for those who need this novel therapeutic.
Why Hoth Therapeutics s Stock is Up During Today s Session benzinga.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from benzinga.com Daily Mail and Mail on Sunday newspapers.
Share this article
Share this article
NEW YORK, April 20, 2021 /PRNewswire/ Hoth Therapeutics, Inc. (NASDAQ: HOTH), a patient-focused clinical-stage biopharmaceutical company, announced that its novel anti-cancer therapeutic exhibited highly positive results in humanized mast cell neoplasm models, representative in vitro and in vivo models for aggressive, mast cell-derived cancers such as mast cell leukemia and mast cell sarcoma. The anti-cancer therapeutic, which is currently in development, uses mRNA frame shifting that induces apoptosis of neoplastic mast cells.
These findings show that the novel anti-cancer therapeutic rapidly induces apoptosis and cell death in neoplastic mast cells. Furthermore, systemic administration of the anti-cancer therapeutic in an
Share this article
LAS VEGAS, April 8, 2021 /PRNewswire/ DelveInsight s
Epidermal Growth Factor Receptor (EGFR) Inhibitors-Induced Skin Disorders Market report provides a thorough comprehension of the EGFR Inhibitors-Induced Skin Disorders, historical and forecasted epidemiology, and the Epidermal Growth Factor Receptor Inhibitors-Induced Skin Disorders market trends in the 7MM [the United States, EU5 (Germany, Spain, Italy, France, and United Kingdom) and Japan]. The EGFR Inhibitors-Induced Skin Disorders market report also proffers an analysis of the current EGFR Inhibitors-Induced Skin Disorders treatment algorithm/practice, market drivers, market barriers, and unmet medical needs.
Some of the key takeaways of the
There is no approved therapy specific for anti-EGFR induced skin diseases in the US, EU, and Japan.
Hoth Therapeutics Engages Worldwide Clinical Trials as Contract Research Organization for Phase 2a HT-001 Clinical Trial for Cancer Patients prnewswire.com - get the latest breaking news, showbiz & celebrity photos, sport news & rumours, viral videos and top stories from prnewswire.com Daily Mail and Mail on Sunday newspapers.